“…131,132,134 As such, complications, including inadequate shape, progressive dimensional change, and donor site morbidity, continue to be problematic. 133,134 Alternative approaches using alloplastic implants, such as silicon or high-density polyethylene (HDPE), have been introduced and approved by the Food and Drug Administration (FDA) for clinical applications. 135,136 Although alloplastic implants are biologically stable and provide several advantages, including no donor site morbidity and long-term structural integrity when compared to autologous costal cartilage tissue, problems with vascularization and tissue integration at the interface between the alloplastic implant and the overlying skin often lead to infection, inflammation, and overlying skin necrosis, resulting in implant failure.…”